← Back to Search

Phosphodiesterase-4 (PDE-4) Inhibitor

Atopic Dermatitis Group for Atopic Dermatitis

Phase 4
Waitlist Available
Led By Anna Fishbein, MD
Research Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and day 28
Awards & highlights

Study Summary

This trial is testing whether a new eczema medication is effective and safe. It will also develop biomarkers to help predict which medication is best for each child with atopic dermatitis.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in expression levels of biomarkers in responder versus non responder groups
Secondary outcome measures
Changes in Quality of life (anxiety, depressive symptoms, fatigue, mobility, pain interference, peer relationships) as assessed by PROMIS Pediatric Profile 25 and Correlation of changes with clinical responsiveness and biomarker PDE4A expression levels
Changes in Quality of life (symptoms and feelings, leisure, school or holidays, personal relationships, sleep, treatment) as assessed by CDLQI and Correlation of Quality of life changes with clinical responsiveness and biomarker PDE4A expression levels
Correlation of TEWL with clinical responsiveness and biomarker PDE4A expression levels

Side effects data

From 2021 Phase 4 trial • 30 Patients • NCT03567980
3%
Facial Pain
3%
Headaches
100%
80%
60%
40%
20%
0%
Study treatment Arm
Topical Crisaborole 2%

Trial Design

1Treatment groups
Experimental Treatment
Group I: Atopic Dermatitis GroupExperimental Treatment1 Intervention
Receive crisaborole intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Crisaborole
2018
Completed Phase 4
~190

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,567 Previous Clinical Trials
10,908,020 Total Patients Enrolled
Ann & Robert H Lurie Children's Hospital of ChicagoLead Sponsor
256 Previous Clinical Trials
5,187,850 Total Patients Enrolled
Anna Fishbein, MDPrincipal Investigator - Ann & Robert H Lurie Children's Hospital of Chicago
Ann & Robert H. Lurie Children's Hospital of Chicago, La Rabida Children's Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of the American Academy of DermatologyJournal
Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults
Paller, Amy S., Wynnis L. Tom, Mark G. Lebwohl, Robin L. Blumenthal, Mark Boguniewicz, Robert S. Call, Lawrence F. Eichenfield, et al.. 2016. “Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults”. Journal of the American Academy of Dermatology. Elsevier BV. doi:10.1016/j.jaad.2016.05.046.
clinicaltrials.govStudy
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
Anna Fishbein, MD 2019. "Response of Children With Atopic Dermatitis (Eczema) to Eucrisa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04023084.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top